Fikri Abali

Dr. Fikri Abali


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2018 in Biosensors
Verified
Journal Article
Open access
PDF file
Richard SchasfoortRichard Schasfoort
Richard Schasfoort
FAFikri Abali
Fikri Abali
ISIvan Stojanovic
Ivan Stojanovic
Gestur VidarssonGestur Vidarsson
Gestur Vidarsson
Leon TerstappenLeon Terstappen
Leon Terstappen
SPR cytometry entails the measurement of parameters from intact cells using the surface plasmon resonance (SPR) phenomenon. Specific real-time and label-free binding of living cells to sensor surfaces has been made possible through the availability of SPR imaging (SPRi) instruments and researchers have started to explore its potential in the last decade. Here we will discuss the mechanisms of detection and additionally describe the problems and issues of mammalian cells in SPR biosensing, both from our own experience and with information from the literature. Finally, we build on the knowledge and applications that has already materialized in this field to give a forecast of some exciting applications for SPRi cytometry.

Verified
Journal Article
Open access
PDF file
KAKiki Andree
Kiki Andree
FAFikri Abali
Fikri Abali
LOLisa Oomens
Lisa Oomens
FPFiona R. Passanha
Fiona R. Passanha
JBJoska J. Broekmaat
Joska J. Broekmaat
Leon TerstappenLeon Terstappen
Leon Terstappen
The availability of viable tumor cells could significantly improve the disease management of cancer patients. Here we developed and evaluated a method using self-seeding microwells to obtain single circulating tumor cells (CTC) and assess their potential to expand. Conditions were optimized using cells from the breast cancer cell line MCF-7 and blood from healthy volunteers collected in EDTA blood collection tubes. 43% of the MCF-7 cells (nucleus+, Ethidium homodimer-1-, Calcein AM+, α-EpCAM+, α-CD45-) spiked into 7.5 mL of blood could be recovered with 67% viability and these could be further expanded. The same procedure tested in metastatic breast and prostate cancer patients resulted in a CTC recovery of only 0–5% as compared with CTC counts obtained with the CellSearch® system. Viability of the detected CTC ranged from 0–36%. Cell losses could be mainly contributed to the smaller size and greater flexibility of CTC as compared to cultured cells from cell lines and loss during leukocyte depletion prior to cell seeding. Although CTC losses can be reduced by fixation, to obtain viable CTC no fixatives can be used and pore size in the bottom of microwells will need to be reduced, filtration conditions adapted and pre-enrichment improved to reduce CTC losses.

2 December 2021 in Cancers
Verified
Journal Article
Open access
PDF file
FAFikri Abali
Fikri Abali
NBNarges Baghi
Narges Baghi
LMLisanne Mout
Lisanne Mout
JBJoska J. Broekmaat
Joska J. Broekmaat
ATArjan G. J. Tibbe
Arjan G. J. Tibbe
Leon TerstappenLeon Terstappen
Leon Terstappen
The treatment of cancer faces a serious challenge as cancer cells within patients are heterogeneous and frequently resistant to therapeutic drugs. Here, we introduce a technology enabling the assessment of single cancer cells exposed to different drugs. PCa cells were individually sorted in self-seeding microwells, cultured for 24 h, and then exposed to several drugs to induce (R1881) or inhibit (Enzalutamide/Abiraterone) the secretion of a protein (PSA). Cell viability and PSA secretion of each individual prostate cell were monitored over a 3-day period. The PSA protein secreted by each cell was captured on a PVDF membrane through a pore in the bottom of each well. The basal PSA secretion was found to be 6.1 ± 4.5 and 3.7 ± 1.9 pg/cell/day for LNCaP and VCaP, respectively. After exposure to R1881, the PSA secretion increased by ~90% on average and was not altered for ~10% of the cells. PSA production decreased in the majority of cells after exposure to enzalutamide and abiraterone.